Latest news

Debiopharm Group™ Announces Initiation of a Phase I Study of Debio 1450, an IV/oral Potent Antibiotic Active Against Staphylococcal Infections

Debiopharm Group™ moves forward three of its oncology clinical programs and will present the recent progresses at the 50th American…

Orient EuroPharma and Debiopharm Group™ announce their partnership and the launch of Pamorelin LA in Singapore

Evotec and Debiopharm Group™ to collaborate on development of new treatment for cancer

Curis and Debiopharm Group™ Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014

Debiopharm Group™ to Acquire Products or Companies to Expand Activities at Manufacturing Facility in Martigny (Valais, Switzerland)

Debiopharm Group™ and Yale University extend and broaden their collaboration for the discovery and development of MIF inhibitors to treat…

Immunexpress Closes USD 6 Million Financing Round led by Debiopharm Group™

Debiopharm Group™ to Acquire Affinium’s Antibiotic Clinical Assets and Platform to Identify and Develop Targeted Antibiotics